Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 12/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18535300 | 0.91 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18009754 | 0.91 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18026298 | 0.88 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL68579 | 0.87 | ADK (0.56) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18009687 | 0.86 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL10131208 | 0.85 | RXFP1 (0.42) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL325253 | 0.85 | RXFP1 (0.42) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL19344078 | 0.82 | PRMT5 (0.38) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18009946 | 0.81 | PRMT5 (0.40) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18009746 | 0.81 | ADK (0.40) | PI4KAPI4K2BPI4K2API4KBADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PI4KA 989/4885PI4K2B 1184/4885PI4K2A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.